Skip to main content
. 2021 May 18;42:100901. doi: 10.1016/j.nmni.2021.100901

Table 1.

Characteristics of included studies

First author Country Viral Etiology Patients CP dose Outcome endpoint Clinical improvement Death Viral therapy Adverse event Weaned ventilation Discharge Drugs Ref
Li China SARS-CoV-2 52 case
51 control
S-RBD–IgG
1:640
200 ml
28 days 27/52
22/51
15.7%
24%
87.2%
37.5%
2/0 NA 51%
36%
Antiviral, antibacterial, antifungal, interferon, steroids [25]
Shen China SARS-CoV-2 5 IgG (1:1000)
200-250 ml
12 days 3 0 5 NA 3 3 Lopinavir/ritonavir, favipiravir, interferon alfa-1b, arbidol, darunavir [26]
Joyner USA SARS-CoV-2 5000 IgG
500 ml
7 days NA 602 NA 36 NA NA NA [27]
Zeng China SARS-CoV-2 6/15 IgG
300 ml
22 days 6 5/6
14/15
6/3 0 NA 1/1 NA [28]
Ahn Korea SARS-CoV-2 2 IgG
500 ml
26 days 2 0 2 0 2 2 Lopinavir/ritonavir, hydroxychloroquine, methylprednisolone, antibiotics [29]
Ye China SARS-CoV-2 6 IgG
400-600 ml
33 days 5 0 2 0 NA 3 Arbidol, levofloxacin [30]
Zhang China SARS-CoV-2 4 IgG
200-400 ml
NA 4 0 4 0 2 4 Arbidol, lopinavir-ritonavir, interferon alpha [31]
Duan China SARS-CoV-2 10 IgG
1:640
200 ml
20 days 10 0 7 0 3 10 Arbidol, remdesivir, ribavirin, peramivir, antibacterial [32]
Ko Korea MERS-CoV 3 IgG
1:80
3 days 3 0 2 NA 3 3 NA [33]
Chun Korea MERS-CoV 1 IgG
500 ml
NA 1 0 NA 1 NA 1 Ribavirin, lopinavir/ritonavir, interferon alpha [34]
Wong China SARS-CoV-1 1 IgG
200 ml
NA 1 0 NA 0 NA 0 Cefotaxime, levofloxacin, oseltamivir, ribavirin [35]
Yeh Taiwan SARS-CoV-1 3 IgG
1:640
500 ml
NA 3 0 2 NA 1 3 Lopinavir, ritonavir, methylprednisolone [36]
Soo China SARS-CoV-1 19/21 IgG
600-900 ml
22 days 14/4 0/5 NA 0 NA 74%
19%
Ribavirin,
methylprednisolone
[37]
Kong China SARS-CoV-1 1 IgG
500 ml
7 days 1 0 NA NA 1 1 Steroids, antiviral [38]
Cheng China SARS-CoV-1 40 IgG
600-900 ml
22 days 40 13 NA 0 NA 26 Cefotaxime, levofloxacin, ribavirin, prednisolone, methylprednisolone [39]